Cytokinetics Incorporated Watch

from 8-K 23 pages Amended and Restated Bylaws of Cytokinetics, Incorporated

from 10-Q 3 pages Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Cytokinetics, Incorporated

from 8-K 19 pages Amended and Restated Bylaws of Cytokinetics, Incorporated

from 8-K 2 pages Certificate of Amendment of Amended and Restated Certificate of Incorporation of Cytokinetics, Incorporated

from 10-Q 2 pages Certificate of Amendment of Amended and Restated Certificate of Incorporation of Cytokinetics, Incorporated [Signature Page Follows]

from S-3 5 pages Amended and Restated Certificate of Incorporation Cytokinetics, Incorporated

from SC 13G ~5 pages Name of Reporting Person Number of Shares (Direct) (5) Number of Shares (Indirect) Percent of Class Beneficially Owned (1) Mayfield IX, a Delaware Limited Partnership 1,781,358 (2) -0- 6.3 % Mayfield IX Management, L.L.C. -0- 1,875,113 (2)(3) 6.6 % Mayfield Associates Fund IV, a Delaware Limited Partnership 93,755 (3) -0- 0.3 % Yogen K. Dalal -0- 2,031,713 (4)(6) 7.2 % F. Gibson Myers, Jr. -0- 2,031,713 (4)(6) 7.2 % Kevin A. Fong -0- 2,031,713 (4)(6) 7.2 % William D. Unger -0- 2,031,713 (4)(6) 7.2 % Wendell G. Van Auken, III -0- 2,031,713 (4)(6) 7.2 % A. Grant Heidrich, III 29,040 (7) 1,875,113 (4) 6.7 % Cell Trust 142,895 0.5 % Cell Trust II 13,705 Total 2,060,753 7.3 %

from S-1 ~20 pages Articles of Incorporation or Bylaws

from S-1 ~5 pages Articles of Incorporation or Bylaws